Anticancer Bioscience (ACB) develops cancer therapies based on synthetic lethality (SL). Our focus is MYC-driven cancers that remain difficult to treat with current therapies.
Founded in 2016 and headquartered in Chengdu Tianfu International BioTown, ACB was established to bring discoveries from the J. Michael Bishop Institute of Cancer Research into clinical development. In close partnership with JMBI, we pursue a treatment strategy that targets dependencies created by oncogenic drivers, rather than the drivers themselves.
ACB’s programs apply MYC biology, synthetic lethality, and architectural control to treat cancer as a sustained malignant state, not as isolated genetic alterations or their networks.
ACB was founded by Dr. Dun Yang, who worked for nearly two decades with Nobel laureate J. Michael Bishop at the University of California, San Francisco. Following Dr. Bishop’s discovery of the cellular origin of oncogenes and his foundational work in MYC biology, Dr. Yang established JMBI as a center for MYC-SL and Architectural Oncology. ACB is the vehicle through which this science is advanced into the clinic
